Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novel camptothecin analog

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1493-1500

  Royce, M E ^a   Hoff, P M ^a   Dumas, P ^a   Lassere, Y ^a   Lee, J J ^a   Coyle, J ^a   Ducharme, M P ^a   De Jager, R ^a   Pazdur, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; EXATECAN;

ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0035281536     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1493     Document Type: Article

References (32)

1. The current status of camptothecin analogues as anti-tumor agents
2. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin
3. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
4. Antitumor activity of DX-8951f: A new camptothecin derivative
5. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo
6. Antitumor effect of DX-8951f, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice
7. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant
8. Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells
9. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
10. Continual reassessment method: A practical design for phase I clinical trials in cancer
11. Some practical improvements in the continual reassessment method for phase I studies
12. Sensitive high-performance liquid chromatographic method for the determination of the lactone and lactone plus hydroxy-acid forms of a new camptothecin derivative, DX-8951 in human plasma using fluorescence detection
13. Gentamicin therapy
14. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
15. An overview of topoisomerase I-targeting agents
16. Clinical applications of the camptothecins
17. Topoisomerase I inhibitors: Review and update
18. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
19. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
20. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
21. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
22. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial
23. US pivotal studies of irinotecan in colorectal carcinoma
24. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
25. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
26. Topotecan: A novel topoisomerase I inhibitor - Pharmacology and clinical experience
27. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
28. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
29. Irinotecan: A review of the initial phase I trials